INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,777,568 | -23.2% | 72,520 | -6.7% | 0.00% | -50.0% |
| Q2 2023 | $4,921,231 | +12.6% | 77,720 | -3.7% | 0.00% | +100.0% |
| Q1 2023 | $4,371,475 | +67.0% | 80,729 | +63.1% | 0.00% | 0.0% |
| Q4 2022 | $2,618,000 | +663.3% | 49,484 | +571.7% | 0.00% | – |
| Q3 2022 | $343,000 | -31.1% | 7,367 | -15.5% | 0.00% | – |
| Q2 2022 | $498,000 | +8.7% | 8,719 | +16.5% | 0.00% | – |
| Q1 2022 | $458,000 | +59.0% | 7,484 | -10.8% | 0.00% | – |
| Q4 2019 | $288,000 | +93.3% | 8,386 | -27.1% | 0.00% | – |
| Q2 2019 | $149,000 | -54.6% | 11,500 | +35.9% | 0.00% | – |
| Q2 2016 | $328,000 | +42.0% | 8,460 | +1.8% | 0.00% | – |
| Q1 2016 | $231,000 | -92.9% | 8,310 | -86.3% | 0.00% | -100.0% |
| Q4 2015 | $3,271,000 | +92.4% | 60,818 | +43.2% | 0.00% | +100.0% |
| Q3 2015 | $1,700,000 | +11.5% | 42,459 | -11.0% | 0.00% | 0.0% |
| Q2 2015 | $1,525,000 | – | 47,720 | +954300.0% | 0.00% | – |
| Q3 2014 | $0 | – | 5 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |